Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial
病理反应和代谢物在接受新辅助吡咯替尼、曲妥珠单抗、白蛋白紫杉醇和卡铂治疗的HER2阳性乳腺癌中的预后作用:一项单臂II期试验
期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-025-02137-z
Liu, Mei; Zou, La; Zhang, Ningning; Zhou, Wenqi; Pan, Xianjun; Deng, Yongchun; Yue, Yeli; Wu, Jing; Liang, Xinrui; Chen, Maoshan; Zeng, Xiaohua